(Q33807710)

29 July 2017

title

RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule (English)

1 reference

29 July 2017

main subject

neoplastic stem cells

1 reference

1 reference

Sarah Shigdar

1

1 reference

29 July 2017

Jia Lin

2

1 reference

29 July 2017

Yan Yu

3

1 reference

29 July 2017

Mile Pastuovic

4

1 reference

29 July 2017

Ming Wei

5

1 reference

29 July 2017

Wei Duan

6

1 reference

29 July 2017

publication date

14 March 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

102

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

991-998

1 reference

Immunoglobulin-like cell adhesion molecules: novel signaling players in epithelial ovarian cancer.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

The emerging role of EpCAM in cancer and stem cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Phenotypic characterization of human colorectal cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Nuclear signalling by tumour-associated antigen EpCAM

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Cancer stem cells in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

EpCAM (CD326) finding its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

EpCAM: A New Therapeutic Target for an Old Cancer Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

In vitro selection of RNA molecules that bind specific ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Using aptamers to visualize and capture cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Ligand-based targeted therapy for cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Aptamers as inhibitors of target proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Technical and biological issues relevant to cell typing with aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Clustal W and Clustal X version 2.0

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Vienna RNA secondary structure server

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Depletion of intracellular potassium disrupts coated pits and reversibly inhibits cell polarization during fibroblast spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Cancer immunotherapy: insights from transgenic animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Developing aptamers into therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Characterisation of aptamers for therapeutic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Retracted: Differential SELEX in Human Glioma Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

The biology of the 17-1A antigen (Ep-CAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Cell-specific internalization study of an aptamer from whole cell selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

Therapeutic applications of aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

A Hitchhiker's guide to HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01897.X

10.1111/J.1349-7006.2011.01897.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference